A Mortal Covid-19 case with SARS-CoV-2 Variant VOC-202012/01 after two doses of CoronaVac® vaccination, case report.

Yıl 2022, Cilt: 39 Sayı: 2, 548 - 550, 18.03.2022

Mehmet Muzaffer İslam Enis Ademoğlu Samet Bayram Merve Osoydan Satıcı Serkan Emre Eroğlu

Öz

Many countries have started their vaccination program against the ongoing COVID-19 pandemic. One of these countries, the Republic of Turkey began to use the CoronaVac® vaccine and a large number of people in the country have been vaccinated so far. The efficacy rate of CoronaVac® vaccine 14 days after two doses was reported as 83% for cases requiring medical treatment and 100% for hospitalization or severe-mortal cases. The effectiveness of the vaccine in subgroups such as patients exposed to SARS-CoV-2 virus in less than 14 days, advanced age, comorbidity, and immunosuppression is not yet known. In addition, its effectiveness against different variants of the SARS-CoV-2 virus is not clear.
An 85-year-old female patient with a positive SARS-CoV-2 Variant VOC-202012/01 Polymerase Chain Reaction test was admitted to the emergency department with dyspnea. The patient, whose tachycardia, tachypnea and auxiliary respiratory muscle use continued despite 60 L / min of 100% oxygen therapy with a high flow nasal cannula and whose PaO2 / fiO2 ratio was 63, was intubated. Bilateral widespread multifocal ground glass densities consistent with COVID-19 were observed in the thorax computed tomography. The patient, who was followed up in the intensive care unit, died on the 11th day of her follow-up.
There are no cases of severe COVID-19 disease reported in the literature yet after the CoronaVac® vaccine. In this case report, we present a severe COVID-19 patient with a positive PCR test for SARS-CoV-2 Variant VOC-202012/01 11 days after the second dose of CoronaVac® administration.

Anahtar Kelimeler

COVID-19, COVID 19 Vaccine, CoronaVac, Acute Respiratory Syndrome Coronavirus 2, Severe COVID-19 Disease

Destekleyen Kurum

-

Proje Numarası

-

Teşekkür

-

Kaynakça

• Reference1. COVID-19 vaccines page. World Health Organization. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines. Accessed April 17, 2021.
• Reference2. Ophinni Y, Hasibuan AS, Widhani A, et al. COVID-19 Vaccines: Current Status and Implication for Use in Indonesia. Acta Med Indones. 2020;52(4):388-412. http://www.actamedindones.org/index.php/ijim/article/view/1648/pdf.Accessed April 17, 2021.
• Reference3. Sinovac Announces Phase III Results of Its COVID-19 Vaccine. Sinovac Biotech Ltd. http://www.sinovac.com/?optionid=754&auto_id=922. Updated February 05, 2021. Accessed April 17, 2021.
• Reference4. Wise J. Covid-19: New coronavirus variant is identified in UK. BMJ 2020;371:m4857. doi:10.1136/bmj.m4857
• Reference5. Rondinone V, Pace L, Fasanella A, et al. VOC 202012/01 Variant Is Effectively Neutralized by Antibodies Produced by Patients Infected before Its Diffusion in Italy. Viruses. 2021;13(2):276. doi: 10.3390/v13020276
• Reference6. Muik A, Wallisch AK, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2021;371(6534):1152-1153. doi: 10.1126/science.abg6105
• Reference7. Covid-19 aşısı bilgilendirme platformu. T.C. Sağlık Bakanlığı. https://covid19asi.saglik.gov.tr. Updated April 17, 2021. Accessed March 17, 2021.
• Reference8. Hertzell KB, Pauksens K, Rombo L, Knight A, Vene S, Askling HH. Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. Vaccine. 2016;34(5):650-655. doi: 10.1016/j.vaccine.2015.12.029
• Reference9. Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;S1473-3099(20)30987-7. doi: 10.1016/S1473-3099(20)30987-7